REGENERON PHARMACEUTICALS INC (REGN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for REGN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| REGN | Director; Chair | 54 | ["Former Chief Information Officer of International Business Machines Corporation (IBM) from 2021 to 2023","Vice President, Chief Operating Officer of IBM Research from 2020 to 2021","Vice President, Industry Research of IBM Research from 2018 to 2020","Vice President, Research Strategy of IBM Research from 2017 to 2018","Vice President, Product Management of IBM Systems from 2014 to 2016","Executive/Leadership Experience","Technology/Digital Experience","Science/Biotech Background","Business Strategy/Operations Experience","Research/Academic Experience"] | ["Audit Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Age: 54 Director since: 2023 Board and Committee Membership 2025 Attendance Board of Directors: 15/15 Audit Committee: 9/9 Career Highlights Former Chief Information Officer of International Business Machines Corporation (IBM) from 2021 to 2023 Previously held positions of increasing responsibility at IBM, including Vice President, Chief Operating Officer of IBM Research from 2020 to 2021; Vice President, Industry Research of IBM Research from 2018 to 2020; Vice President, Research Strategy of IBM Research from 2017 to 2018; and Vice President, Product Management of IBM Systems from 2014 to 2016 Experience and Expertise Executive/Leadership Experience Technology/Digital Experience Science/Biotech Background Business Strategy/ Operations Experience Research/Academic Experience Dr. Guarini s experience as an executive of a major corporation and extensive knowledge of information technology, data security, and artificial intelligence matters led the board to conclude that Dr. Guarini should serve as a director.